Three-factor tool may predict response to UDCA in PBC: Study
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…
A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than 16 times, but it likely…
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…
In 2024, Liver Disease News kept readers informed aboout liver disease research, treatments, and clinical trials. Here are the 10 most read stories, each with…
A modified version of the Simple Biliary Atresia Scoring System (SBASS) offers a noninvasive way for doctors to make a biliary atresia diagnosis, differentiating…
Software tools may help predict whether certain hard-to-interpret mutations in the JAG1 gene affect splicing, a process that can direct how a protein is produced,…
The U.S. Food and Drug Administration (FDA) is still reviewing Intercept Pharmaceuticals’ application for full approval of Ocaliva (obeticholic acid) as a second-line…
Ipsen’s Kayfanda (odevixibat) has been approved, under exceptional circumstances, in the European Union (EU) to treat cholestatic pruritus in people with Alagille syndrome,…
Iqirvo (elafibranor) has been conditionally approved in the European Union to treat adults with primary biliary cholangitis (PBC), either in combination with the…
Abnormal levels of certain fatty molecules, or lipids, in the blood appear to increase the risk of intrahepatic cholestasis of pregnancy (ICP) and its…